0001209191-20-064654.txt : 20201221
0001209191-20-064654.hdr.sgml : 20201221
20201221164347
ACCESSION NUMBER: 0001209191-20-064654
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201217
FILED AS OF DATE: 20201221
DATE AS OF CHANGE: 20201221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAY MARY ANN
CENTRAL INDEX KEY: 0001261974
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 201404798
MAIL ADDRESS:
STREET 1: 201 W 70TH ST, SUITE 23K
CITY: NEW YORK
STATE: NY
ZIP: 10023
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-17
0
0001664710
Keros Therapeutics, Inc.
KROS
0001261974
GRAY MARY ANN
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
1
0
0
0
Stock Option (right to buy)
82.74
2020-12-17
4
A
0
16587
0.00
A
2030-12-16
Common Stock
16587
16587
D
One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on March 17, 2021, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante, Attorney-in-Fact
2020-12-21